Resistance and treatment strategy of gastrointestinal stromal tumor target therapy.
- Author:
Wei LU
1
;
Wei-qi LU
Author Information
1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. dr.luwei@fudan.edu.cn
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Benzamides;
therapeutic use;
Drug Resistance, Neoplasm;
genetics;
Gastrointestinal Stromal Tumors;
drug therapy;
genetics;
Humans;
Imatinib Mesylate;
Indoles;
therapeutic use;
Piperazines;
therapeutic use;
Protein Kinase Inhibitors;
therapeutic use;
Pyrimidines;
therapeutic use;
Pyrroles;
therapeutic use
- From:
Chinese Journal of Gastrointestinal Surgery
2012;15(3):309-312
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumor(GIST) originates from interstitial cells of Cajal(ICCs). Tyrosine kinase inhibitors(TKI) such as imatinib and sunitinib, are effective agents besides surgery. However some GIST can become primarily or secondarily resistant to those drugs. The difference in gene mutation types and secondary gene mutation is the main cause. When the GIST is proved to be drug resistance, reasonable personal treatment strategies based on individualized medicine should be made to improve outcomes and quality of life.
